Contraindications: Testosterone Propionate is contraindicated in individuals with known or suspected androgen-sensitive prostate or breast carcinoma, active hepatic impairment, untreated polycythaemia, or hypersensitivity to any constituent of the formulation including the carrier oil. Individuals under 21 are strongly discouraged from use, as the endocrine system remains in active development.
Side Effects: Androgenic effects may include accelerated scalp hair thinning in genetically predisposed individuals, acne, and increased sebaceous secretion. Estrogenic effects arising from aromatisation — fluid retention, gynaecomastia — are dose-dependent and manageable with an aromatase inhibitor. Injection-site reactions (localised soreness, transient warmth) are common with propionate and typically resolve within 24–48 hours; rotating injection sites reduces accumulation.
Monitoring: Beginners should obtain pre-cycle bloodwork covering total testosterone, free testosterone, estradiol, LH, FSH, haematocrit, lipid panel, and liver enzymes. Repeat bloodwork at mid-cycle (week 4) and at PCT completion is recommended to confirm physiological parameters are within acceptable ranges. Blood pressure should be self-monitored throughout the cycle.
PCT: Because propionate's ester clears comparatively quickly, SERM-based post-cycle therapy can commence within three to four days of the final injection. A standard nolvadex or clomid protocol (e.g., four weeks with tapering dose) is appropriate for a beginner's first cycle. Failure to complete PCT increases the risk of prolonged suppression of the hypothalamic–pituitary–testicular axis.